safe compounded semaglutide FDA warns against using Semaglutide for weight loss |

Reevaluate metabolic status prior to discontinuing and restarting GLP-1 therapy, measure HbA1c, electrolytes, and fasting glucose and document any insulin requirements to assist in safe resumption

Semaglutide and tirzepatide in Long Beach are FDA-approved for weight loss, but they are not appropriate for everyone

Mounjaro cardiovascular outcomes data is still pending (SURPASS-CVOT expected 2029)

Options include staying at your current dose longer before increasing, temporarily reducing to your previous dose level, implementing more aggressive side effect management strategies, or in some cases discontinuing treatment

Chances are, if youre reading this, youre already well aware of the class of drugs known as GLP-1 receptor agonists such as Ozempic and Wegovy

"Will I regain weight after stopping medication?" Evidence suggests weight often returns after stopping GLP-1 treatment, which is why clinician-led maintenance planning and lifestyle support are important